Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $1.00B
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.83M
Average 1.07M
Returns on capital
Vor Biopharma Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
423.6%
avg -1.8%
ROIC
-84.6%
avg -47.7%
ROA
-150.0%
avg -115.9%
Analysis
ROE is currently the strongest return metric at 423.6% versus its period average of -1.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Robert Ang MBBS | Strategic Advisor | USD 2M | 52 | — | — |
Jean-Paul Kress | Chairman, President & CEO | USD 1.01M | 61 | 0 | <0.01% |
Jeremy Sokolove | Chief Medical Officer | USD 695.16K | 52 | — | — |
Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | USD 603.81K | 61 | 0 | <0.01% |
Navid Z. Khan | Chief Medical Affairs Officer | — | — | — | — |
Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | — | 55 | — | — |
Adi Osovsky | General Counsel | — | — | — | — |
Carol Lincoln | Head of Human Resources | — | — | — | — |
Dallan Murray | Chief Commercial Officer | — | 56 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 5, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$49.42M
Net Transaction Value
−$49.42M
Net selling
Most Active
RA CAPITAL MANAGEMENT, L.P.
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 16, 26Jul 16, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $4.2K$4,206.75 |
| Apr 22, 26Apr 22, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $2.6M$2,604,415.50 |
| Apr 20, 26Apr 20, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $2.7M$2,711,856.51 |
| Apr 17, 26Apr 17, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $7.5M$7,462,931.08 |
| Apr 15, 26Apr 15, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $858.8K$858,840.44 |
| Apr 14, 26Apr 14, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $2.5M$2,455,147.95 |
| Apr 13, 26Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $8.6M$8,569,351.50 |
| Apr 10, 26Apr 10, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $13K$13,041.00 |
| Apr 9, 26Apr 9, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $2.2M$2,242,984.59 |
| Apr 8, 26Apr 8, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Sell | $5.8M$5,764,909.44 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $49.42M over the last 12 months. That adds up to net selling of $49.42M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Vor Biopharma Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about VOR's management, answered from reported figures.
Who manages VOR?
Vor Biopharma Inc. (VOR) lists 9 active executives. The top listed executive is Jeremy Sokolove, Chief Medical Officer.
Are VOR insiders buying or selling?
Recent insider activity shows net selling of $100.06M.
Continue the stock analysis
Jump to another research area for this company.